NCT04809792Not yet recruiting
MR-Linac for Head and Neck SBRT
Magnetic Resonance Imaging-Guided Radiotherapy for Head & Neck SBRT on the 1.5T MR-Linac
Source: ClinicalTrials.gov · Last updated 23 May 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study will evaluate the feasibility and safety of using MR-guided adaptive Head and Neck stereotactic radiotherapy (SBRT) at each fraction on the 1.5T MR-Linac.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 15 Mar 2021
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Diseases
- Head and neck cancer
- NCT number
- NCT04809792
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Jun 2023 to the primary completion date, 1 Jun 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of radiation within the projected treatment field
- Patients with connective tissue disorders
- History of severe claustrophobia
Lab values
- Having an estimated glomerular filtration rate (GFR) \<40 ml/min/1.73m2
Other
- Contraindications to MR imaging per institutional policy
- Pregnant and or breastfeeding females
Who the study is looking for
- Patients aged 18 years and older
- Karnofsky performance status score of ≥70
- Biopsy-proven oligometastatic cancer to the HN
- Biopsy-proven primary HN cancer (either mucosal, nodal, skin)
- Patients deemed unsuitable by the treating radiation oncologist for radiation treatment with curative intent owing to advanced age, significant comorbidities, poor performance status, distant metastatic disease.
- ≥ 1 site amenable to HN SBRT
- Capable of providing informed consent
- Required to complete any systemic therapy ≥ 10 days prior to planned start of HN SBRT, with no plans to initiate systemic therapy ≥10 days following completion of HN SBRT.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.